Isabelle Ray-Coquard
伊莎贝尔·雷-科夸尔
MD, PhD
Head of Department of Medical Oncology; Professor of Medical Oncology医学肿瘤学系主任；医学肿瘤学教授
👥Biography 个人简介
Isabelle Ray-Coquard, MD, PhD is Head of Medical Oncology at Centre Léon Bérard in Lyon and a leading European expert in ovarian and rare gynecologic tumors. She is the principal investigator of the landmark PAOLA-1/ENGOT-ov25 trial, which demonstrated that maintenance olaparib plus bevacizumab significantly extended progression-free survival after first-line platinum-taxane plus bevacizumab in advanced ovarian cancer, particularly in patients with BRCA mutations or HRD. Dr. Ray-Coquard co-chairs the GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire) trial group and leads European initiatives for rare gynecologic cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PAOLA-1 Trial — Olaparib + Bevacizumab Maintenance
Conducted the pivotal PAOLA-1/ENGOT-ov25 trial demonstrating that olaparib maintenance added to bevacizumab after first-line chemotherapy nearly doubled PFS in HRD-positive advanced ovarian cancer, establishing a new standard of care in France and Europe.
Rare Gynecologic Tumor Research
Leads European research consortia for rare tumors including granulosa cell tumors, uterine sarcomas, and small cell carcinoma of the ovary, establishing diagnostic criteria and treatment frameworks for these under-studied malignancies.
GINECO Clinical Trial Leadership
Co-chairs the GINECO trial group, one of Europe's most productive gynecologic oncology cooperative groups, overseeing design and execution of pivotal phase II/III trials across all gynecologic cancer types.
Representative Works 代表性著作
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1/ENGOT-ov25)
New England Journal of Medicine (2019)
Landmark phase III trial establishing olaparib plus bevacizumab maintenance as standard of care in HRD-positive advanced ovarian cancer after first-line platinum-based chemotherapy.
Pembrolizumab in Women with Previously Treated Advanced Uterine Leiomyosarcoma
Annals of Oncology (2021)
Phase II data on checkpoint inhibitor activity in uterine sarcoma, supporting immunotherapy strategies in rare gynecologic tumors.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 伊莎贝尔·雷-科夸尔 的研究动态
Follow Isabelle Ray-Coquard's research updates
留下邮箱，当我们发布与 Isabelle Ray-Coquard（Centre Léon Bérard, Université Claude Bernard Lyon 1）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment